Чистогестагенная имплантационная контрацепция (обзор международных клинических рекомендаций)
https://doi.org/10.21518/2079-701X-2015-XX-5-6
Аннотация
В статье представлен обзор международных клинических рекомендаций по чистогестагенной имплантационной контрацепции. Приведены данные об эффективности, безопасности, рисках и побочных эффектах применения подкожных имплантатов Импланон и Импланон НКСТ.
Список литературы
1. TrusseLL J, Henry N, Hassan F, et al. Burden of unintended pregnancy in the United States: potential savings with increased use of Long-acting reversible contraception. Contraception. 2013, 87: 154-161.
2. Winner B, Peipert JF, Zhao 0 et al. Effectiveness of Long-acting reversible contraception. N Engl J Med, 2012, 366: 1998-2007.
3. American College of Obstetricians and Gynecologists: Long-acting reversible contraception: Implants and intrauterine devices. Obstet Gynecol, 2011, 121: 13 p.
4. Blumenthal P, Gemzell-Danielsson K, Marintcheva-Petrova M. Tolerability And Clinical Safety of IMPLANON®. Eur J Contrac and Reprod Health Care, 2008, 13(S1): 29-36.
5. WHO. Medical eligibility criteria for contraceptive use. Fouth edition, 2009.
6. Graesslin O, Korver T. The contraceptive efficacy of Implanon: a review of clinical trials and marketing experience. Eur J Contracept Reprod Health Care, 2008, 13(Sl.1): 4-12.
7. Kloosterboer HJ, Vonk-Noordegraaf CA, Turpijn EW. Selectivity in progesterone and androgen receptor binding of progestagens used in oral contraceptives. Contraception, 1988, 38(3): 325-332.
8. Makarainen L, van Beek A, Tuomivaara L et al. Ovarian function during the use of a single contraceptive implant: Implanon compared with Norplant. Fertil Steril, 1998, 69: 714-721.
9. Wenzl R, Van Beek A, Schnabel P, et al. Pharmacokinetics of etonogestrel released from the contraceptive implant Implanon. Contraception, 1998, 58: 283-288.
10. Faculty of Sexual & Reproductive Health Care Clinical Guidance. Progestogen-only Implants. Clinical Effectiveness Unit, 2014. http//Www.fsrh. org/pdfs/CEUGuidanceProgestogenOnlylmplants.pdf
11. Meiri K, Brashe V, Orawan K et al. Multicenter randomized clinical trial of one-rod etonogestrel and two-rod levonoergestrel contraceptive implants with nonrandomized coop-er-IUD controls: methodologe and insection data. Contraception, 2013, 87: 113-120.
12. Rekers H. Removal of a fractured Nexplanon: MSD response. J Fam Plann Reprod Health Care, 2013, 39: 67-72.
13. Bensouda-Grimaldi L, Jonville-Bera AP, Beau-Salinas F et al. Insertion problems, removal problems and contraception failures with Implanon. Gynecol Obstet Fertil, 2005, 33: 986-990.
14. Mansour D, Fraser IS, Walling M, et al. Methods of accurate localisation of non-palpable sub-dermal contraceptive implants. J Fam Plann Reprod Health Care, 2008, 34: 9-12.
15. Hatcher RA, Trussel J, Nelson AL et al. Contraceptive Technology. 19th revised ed. New York, NY: Ardent Media, 2007.
16. Lidegaard O, Lokkegaard E, Jensen A, et al. Thrombotic Stroke and Myocardial Infarction with Hormonal Contraception. N Engl J Med, 2012, 366: 22572266.
17. Lidegaard O, Nielsen LH, Skovlund CW, Lokkegaard E. Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10. BMJ, 2012, 344: e2990.
18. Brito MB, Rui A, Ferriani JCM. Effects of the etonogestrel-releasing contraceptive implant inserted immediately postpartum on maternal hemostasis: A randomized controlled trial. Thrombosis Research, 2012, 130: 355-360.
19. Allen RH, Cwiak CA, Kaunitz AM. Contraception in women over 40 years of age. CMAJ, 2013, 185: 565-573.
20. Bitzer J, Tschudin S, Alder J. Acceptability and side-effects of Implanon in Switzerland: A retrospective study by the Implanon Swiss Study Group. Eur J Contracept Reprod Health Care, 2004, 9: 278-284.
21. Dilbaz B, Ozdegirmenci O, Caliskan E et al. Effect of etonogestrel implant on serum lipids, liver function tests and hemoglobin levels. Contraception, 2010, 81: 510-514.
22. Mornar S, Lingtak-Neander C, Mistretta S et al. Pharmacokinetics of the etonogestrel contraceptive implant in obese women. Am J Obstet Gynecol, 2012, 207: e1-e6.
23. Xu H, Wade JA, Peipert JF et al. Contraceptive failure rates of etonogestrel subdermal implants in overweight and obese women. Obstet Gynaecol, 2012, 120: 21-26.
24. Mol BW, Ankum WM, Bossuyt PM, Van der Veen F. Contraception and the risk of ectopic pregnancy: a meta-analysis. Contraception, 1995, 52: 337-344.
25. Reinprayoona D, Taneepanichskula S, Bunyavejchevina S et al. Effects of the etonogestrel-releasing contraceptive implant (Implanon®) on parameters of breastfeeding compared to those of an intrauterine device. Contraception, 2000, 62: 239-246.
26. Darney P, Patel A, Rosen K et al. Safety and efficacy of a single-rod etonogestrel implant (Implanon): results from 11 clinical trials. Fertil Steril, 2009, 91: 1646-1653.
27. Mansour D, Korver T, Marintcheva-Petrova M. The Effects of IMPLANON® on Menstrual Bleeding Patterns. Eur J of Contrac Reprod Health Care, 2008, 13(S1): 13-28.
28. Walch K, Unfried G, Huber J et al. Implanon versus medroxyprogesterone acetate: effects on pain scores in patients with symptomatic endometriosis - a pilot study. Contraception, 2009, 79: 29-34.
29. Patel A, Schwarz EB, Society of Family Planning. Cancer and contraception. SFP Guideline. Contraception, 2012, 86: 191-198.
30. Mascarenhas L, van Beek A, Bennink HC, Newton J. A 2-year comparative study of endo-metrial histology and cervical cytology of contraceptive implant users in Birmingham, UK. Hum Reprod, 1998, 13: 3057-3060.
31. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet, 1996, 347: 1713-1727.
32. Pongsatha S, Ekmahachai M, Suntornlimsiri N et al. Bone mineral density in women using the subdermal contraceptive implant Implanon for at least two years. Int J Gynaecol Obstet, 2010, 109: 223-225.
33. Lopez LM, Frimes D, Schulz KF, Curtis KM. Steroidal contraceptives: effect on bone fractures in women. Cochrane Database Syst Rev, 2011, 7: CD006033.
34. National Institute for Health and Care Excellence (NICE). Long-acting Reversible Contraception: The Effective and Appropriate Use of Long-acting Reversible Contraception, 2005. http//guidance.nice.org.uk/CG30
35. Lopez LM, Edelman A, Chen M et al. Progestin-only contraceptives: effects on weight. Cochrane Database Syst Rev., 2013, 7: CD008815.
36. Harrison-Woolrych M, Hill R. Unintended pregnancies with the etonogestrel implant (Impla-non): a case series from postmarketing experience in Australia. Contraception, 2005, 71: 306-308.
37. Singh M, Mansour D, Richardson D. Location and non-palpable Implanon implants with the aid of ultrasound guidance. J Fam Plann Reprod Health Care, 2006, 32: 153-156.
38. Faculty of Sexual & Reproductive Health Care Clinical Guidance. Drug Interactions with Hormonal Contraception, 2011. http//www.fsrh.org/pdfs/ CEUGuidanceDrugInteractionsHormonal.pdf
39. Cooling H, Pauli H. Full term pregnancy with Implanon in situ. J Fam Plann Reprod Health Care, 2006, 32: 204-210.
40. Church E, Sengupta S, Chia KV. The contraceptive implant for long acting reversible contraception in patients undergoing first trimester medical termination of pregnancy. Sex Reprod Health, 2010, 1: 105-109.
41. World Health Organization. Safe Abortion: Technical and Policy Guidance for Health Systems (2nd ed.). Geneva, Switzerland: World Health Organization, 2012.
42. Abdel-aleem H, dArcangues C, Vogelsong K et al. Treatment of vaginal bleeding irregularities induced by progestin only contraceptives. Cochrane Database Syst Rev., 2007(4): CD003449.
43. Faculty of Sexual and Reproductive Health Care. Management of unscheduled bleeding in women using hormonal contraception, 2009.
44. Weisberg E, Hickey M, Palmer D et al. A randomized controlled trial of treatment options for troublesome uterine bleeding in Implanon Users. Hum Reprod, 2009, 24: 1852-1861.
45. Lopez LM, Steiner M, Grimes DA et al. Strategies for communicating contraceptive effectiveness. Cochrane Database Syst Rev, 2013, 4: CD006964.
46. WHO, 2003. Progress in Reproductive health Research, №61.
47. Адамян Л.В. Клиника, диагностика и лечение генитального эндометриоза. Акуш. и гин., 1992, 7: 54-59.
48. Ludicke F1, Sullivan H, Spona J, Elstein M. Dose finding in a low-dose 21-day combined oral contraceptive containing gestodene. Contraception, 2001, Oct., 64(4): 243-8.
49. Walch K, Unfried G, Huber J, Kurz C, Trotsenburg M, Pernicka E et al. Implanon® versus medroxyprogesterone acetate: effects on pain scores in patients with symptomatic endome-triosis - a pilot study. Contraception, 2009, 79: 29-34.
Рецензия
Для цитирования:
Пустотина ОА. Чистогестагенная имплантационная контрацепция (обзор международных клинических рекомендаций). Медицинский Совет. 2015;(XX):5-6. https://doi.org/10.21518/2079-701X-2015-XX-5-6
For citation:
Pustotina OA. Progestin-only implant contraception (a review of global clinical guidelines). Meditsinskiy sovet = Medical Council. 2015;(XX):5-6. (In Russ.) https://doi.org/10.21518/2079-701X-2015-XX-5-6
Просмотров:
464
Послать статью по эл. почте 